10 April 2025NewsEuropeIna vom Feld and Maximilian Kücking

Patent pledges in global crises: Why Moderna prevailed over Pfizer/BioNTech

The Düsseldorf court’s decision offers an instructive perspective on the legal nature of patent pledges as well as a reminder that it is risky to rely solely on informal public declarations, say Ina vom Feld and Maximilian Kücking of Herbert Smith Freehills.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Eli Lilly piles on weight loss drug suits to ward off revenue squeeze

3 April 2025 Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing competition and patent expiration increase urgency for Lilly | New Jersey and Delaware stores accused of selling unapproved tirzepatide-based products.

Americas

Patent cliff: 5 blockbusters running out of road

1 April 2025 MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.

Americas

Takeda, Pfizer, and Sumitomo sue to protect $379m Orgovyx revenue

20 March 2025 Trio files multiple patent infringement lawsuits to protect blockbuster prostate cancer drug | Latest suits target Hetero and Aizant, following similar actions against Apotex, BDR Pharmaceuticals, and CIPLA.